OpGen said it intends to use the proceeds of the offering to complete its acquisition of German molecular diagnostics firm Curetis, among other things.
If the underwriters exercise their option to purchase the over-allotment in full, total gross proceeds from the offering would be $230 million.
The company said it processed around 200,000 tests in the third quarter, representing approximately 20 percent growth over the year-ago quarter.
The proceeds from the sale will go toward the planned acquisition of Curetis and to support the ongoing submission of its technology to US regulators.
The firm has launched both a public offering of common stock as well as a private placement of warrants, expecting to bring in around $20 million from the transactions.
Exagen, which develops and markets autoimmune tests, went public on the Nasdaq today and expects gross proceeds of $50.4 million from its IPO.
The firm is offering approximately 13.8 million shares and the same number of warrants to purchase shares, which will be sold together.
The genetic testing firm has entered into an equity distribution agreement with Piper Jaffray to offer up to $30 million in stocks, with an initial offering of $22.5 million.
The firm offered more than 2.7 million shares of its common stock, including 356,435 shares to its underwriters pursuant to an option to purchase additional shares.
The firm it plans to offer from time to time units of its common stock, preferred stock, one or more debt securities, warrants, or rights to such securities in one or more series.